SCHEMBL2985396

SCHEMBL2985396

Cc1cnc(S(C)(=O)=O)nc1-c1ccc(Br)s1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HSD17B10 Q99714 3/20 0.39
ALOX12 P18054 2/20 0.39
ALOX15 P16050 1/20 0.39
ALDH1A1 P00352 5/20 0.35
PTGS2 P35354 3/20 0.33
PTGS1 P23219 2/20 0.33
RORC P51449 1/20 0.33
KDM4E B2RXH2 4/20 0.33
LMNA P02545 3/20 0.33
POLB P06746 2/20 0.33
PPARG P37231 2/20 0.33
NCOA2 Q15596 2/20 0.33
RXFP1 Q9HBX9 2/20 0.33
ABL1 P00519 1/20 0.33
NPC1 O15118 3/20 0.32
TP53 P04637 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5170747 0.90 MAPT (0.33) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL3967424 0.76 MAPT (0.42) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL2988938 0.75 KMT2A (0.45) MEN1KMT2AHSD17B10ALDH1A1PTGS2
SCHEMBL2198259 0.75 KDM4E (0.38) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL2983865 0.74 MAPT (0.41) MAPTMEN1KMT2AHSD17B10ALOX12
SCHEMBL2350715 0.69 MAPT (0.42) MAPTMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL3572469 0.67 CYP2A6 (0.51) ALDH1A1PTGS2PTGS1LMNAPOLB
SCHEMBL10582722 0.66 TP53 (0.41) MAPTMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL22489959 0.64 TP53 (0.46) MAPTMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL22673994 0.64 TP53 (0.40) MAPTHSD17B10ALDH1A1RORCLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831207-B1 AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS AMGEN INC (US) 2012-11-14 EP disclosed
CN-101115749-B Aminopyrimidine compounds and methods of use AMGEN INC 2011-06-22 CN disclosed
US-7858785-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-12-28 US disclosed
US-7786132-B2 Aminopyrimidine compounds and methods of use AMGEN INC. (US) 2010-08-31 US disclosed
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN INC. (US) 2010-01-14 US disclosed
CN-101115749-A Aminopyrimidine compounds and methods of use AMGEN INC (US) 2008-01-30 CN disclosed
EP-1831207-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE Amgen Inc. (US) 2007-09-12 EP disclosed
US-20070185133-A1 Aminopyrimidine compounds and methods of use AMGEN, INC. (US) 2007-08-09 US disclosed
WO-2006066172-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE AMGEN, INC. (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010014-A1 AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE PLK1, TYMP, TK2 MAPT 1412/4885MEN1 3920/4885KMT2A 1112/4885
US-20070185133-A1 Aminopyrimidine compounds and methods of use PLK1, TYMP, TK2 MAPT 1412/4885MEN1 3920/4885KMT2A 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.